Erectile Dysfunction
Conditions
Keywords
Erectile dysfunction, Mirodenafil, Bravonto
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of mirodenafil in participants with erectile dysfunction.
Detailed description
This is a non randomized (the study medication is not assigned by chance), open-label (all participants and study staff know the identity of the treatment), multi-center, prospective (looking forward using observations collected following participant enrollment), and non-comparative study in which participants with erectile dysfunction will be observed to evaluate the safety and effectiveness of mirodenafil for 12 weeks. Safety evaluations will include assessment of adverse events, and record of concomitant medications. The study will be conducted in Korea.
Interventions
DRUGNo intervention
This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
Sponsors
Janssen Korea, Ltd., Korea
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants diagnosed with erectile dysfunction * Participants prescribed mirodenafil on demand
Exclusion criteria
\- Participants who have administered mirodenafil for other than an approved indication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Up to 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| International Index of Erectile Function | Baseline (Week 0), Week 4, Week 8, and Week 12 | The International Index of Erectile Function is used for the assessment of erectile dysfunction, with scores ranging from 0 to 30. Evaluation of points are as follows: 1-10 = severe erectile dysfunction, 11-16 = moderate dysfunction, 17-21 = mild to moderate dysfunction, 22-25 = mild dysfunction, 26-30 = no dysfunction. Lower scores indicate worsening. |
| Sexual Encounter Profile | Baseline (Week 0), Week 4, Week 8, and Week 12 | The Sexual Encounter Profile is assessed after each sexual attempt consisting of a series of yes/no questions regarding specific aspects of each encounter. Question 1 asks, Were you able to insert your penis into your partner's vagina? and question 2 asks, Did your erection last long enough for you to complete intercourse with ejaculation?. |
| Global assessment Questionnaire | Baseline (Week 0), Week 4, Week 8, and Week 12 | The Global Assessment Questionnaire is a self-administered questionnaire (Yes/No) that allows men to rate improvement in erectile function. Question 1 asks Has the treatment you have been taking over the past 4 weeks improved your erections? and if the answer is yes, question 2 then asks Has the treatment improved your ability to engage in sexual activity |
| Number of participants with adverse events | Up to 12 weeks | — |
Outcome results
None listed